FDA chief defends approval of hydrocodone drug

The head of the Food and Drug Administration says the much-debated painkiller Zohydro fills an "important and unique niche" for treating pain.

Dr. Margaret Hamburg defended her agency's decision to clear the drug during questioning before a Senate committee on Thursday, saying the pill from Zogenix met the government's standards for safety and effectiveness.

Zohydro is the first pure version of hydrocodone, the most abused medication in the U.S. More than a half-dozen lawmakers have criticized the FDA's approval decision, questioning why Zohydro was not formulated to thwart drug abusers from snorting or injecting it.

Hamburg cautioned that such formulations are still in the early stages of development. To date, the FDA has only approved one medication with such features: OxyContin.

"Right now, unfortunately, the technology is poor," Hamburg said.

Related Stories

Sen. Joe Manchin seeks to block new painkiller

date Mar 11, 2014

U.S. Sen. Joe Manchin is calling on the government's top health official to overturn the approval of a powerful painkiller, arguing that the pill Zohydro could add to the national epidemic of prescription drug abuse.

US panel opposes pure hydrocodone painkiller

date Dec 09, 2012

(AP)—U.S. government health experts overwhelmingly voted against a stronger version of hydrocodone on Friday, questioning the need for a new form of one of most widely abused prescription painkillers.

Potent new painkiller stokes alarm in US

date Mar 08, 2014

A potent new painkiller hit the US market this week, despite warnings from top experts that the drug may deliver a deadly setback in America's battle with opioid addiction.

Recommended for you

Joint search for new antibiotics

date 2 hours ago

The WHO has identified antibiotic resistance as one of the three biggest threats to human health. Without new antibiotics, we risk returning to a situation in which every infection is life-threatening. The ...

Mylan rebuffs Teva again; calls bid low, insincere

date 23 hours ago

Generic drug company Mylan rejected for the second time Monday a $40.1 billion takeover offer from Israeli pharmaceutical power Teva, just days after Mylan's own bid for rival Perrigo was rebuffed.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.